Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morten Andersen

Showing results (171-180 of 197) with videos related to

Pageof 20
Sort By:
Plos One|September 1, 2017
Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer developmentMorten Andersen, Zamra Sajid, Rasmus K Pedersen, et al.
Frontiers in Immunology|September 4, 2023
Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrowMorten Orebo Holmström, Morten Andersen, Sofie Traynor, et al.
Frontiers in Immunology|June 7, 2024
Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasmsTobias Idor Boklund, Jordan Snyder, Johanne Gudmand-Hoeyer, et al.
Diabetologia|June 3, 2017
Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort studyAnna But, Marie L De Bruin, Marloes T Bazelier, et al.
Clinical Genitourinary Cancer|November 1, 2025
Nationwide Real-World Outcomes of Trial Eligible and Trial Ineligible Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus IpilimumabMette Syberg Jespersen, Jesper Andreas Evers Palshof, Niels Fristrup, et al.
Pharmaceuticals (Basel, Switzerland)|October 8, 2016
Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?Brian Godman, William Shrank, Bjorn Wettermark, et al.
Current Drug Safety|November 13, 2013
CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysisJakob Starup-Linde, Oystein Karlstad, Stine Aistrup Eriksen, et al.
Cancer Medicine|January 29, 2020
Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasmsRasmus K Pedersen, Morten Andersen, Trine A Knudsen, et al.
British Journal of Clinical Pharmacology|July 7, 2020
Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillationPatrick C Souverein, Hendrika A van den Ham, Consuelo Huerta, et al.
Nature Genetics|February 16, 2026
Modeling the evolutionary dynamics of clonal hematopoiesisSadegh Marzban, Thomas Stiehl, Zhuoer Xie, et al.
Pageof 20

Showing results (171-180 of 197) with videos related to

Sort By:
Pageof 20
Plos One|September 1, 2017
Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer developmentMorten Andersen, Zamra Sajid, Rasmus K Pedersen, et al.
Frontiers in Immunology|September 4, 2023
Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrowMorten Orebo Holmström, Morten Andersen, Sofie Traynor, et al.
Frontiers in Immunology|June 7, 2024
Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasmsTobias Idor Boklund, Jordan Snyder, Johanne Gudmand-Hoeyer, et al.
Diabetologia|June 3, 2017
Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort studyAnna But, Marie L De Bruin, Marloes T Bazelier, et al.
Clinical Genitourinary Cancer|November 1, 2025
Nationwide Real-World Outcomes of Trial Eligible and Trial Ineligible Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus IpilimumabMette Syberg Jespersen, Jesper Andreas Evers Palshof, Niels Fristrup, et al.
Pharmaceuticals (Basel, Switzerland)|October 8, 2016
Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?Brian Godman, William Shrank, Bjorn Wettermark, et al.
Current Drug Safety|November 13, 2013
CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysisJakob Starup-Linde, Oystein Karlstad, Stine Aistrup Eriksen, et al.
Cancer Medicine|January 29, 2020
Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasmsRasmus K Pedersen, Morten Andersen, Trine A Knudsen, et al.
British Journal of Clinical Pharmacology|July 7, 2020
Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillationPatrick C Souverein, Hendrika A van den Ham, Consuelo Huerta, et al.
Nature Genetics|February 16, 2026
Modeling the evolutionary dynamics of clonal hematopoiesisSadegh Marzban, Thomas Stiehl, Zhuoer Xie, et al.
Pageof 20